5F-PCN (also known as 5F-MN-21) is an azaindole-based
synthetic cannabinoid that is presumed to be a potent
agonist of the
CB1 receptor and has been sold online as a
designer drug.[1][2] It is closely related to
NNE1. Given the known metabolic liberation (and presence as an impurity) of
amantadine in the related compound
APINACA, it is suspected that metabolic hydrolysis of the amide group of 5F-PCN may release
1-naphthylamine, a known
carcinogen.
Legal status
Sweden's public health agency suggested to classify 5F-PCN as hazardous substance on November 10, 2014.[3]
^"5F-PCN". Cayman Chemical. Retrieved 22 July 2015.
^Blaazer AR, Lange JH, van der Neut MA, Mulder A, den Boon FS, Werkman TR, et al. (October 2011). "Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity". European Journal of Medicinal Chemistry. 46 (10): 5086–98.
doi:
10.1016/j.ejmech.2011.08.021.
PMID21885167.